Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Therapeutic equivalence of twice-daily aspirin 50 mg versus once-daily aspirin 100 mg in adults with CAD, PAD, or recent ACS
2023-000135-76Phase 3Completed
- Sponsor
- Adamed Pharma
- Start
- Mar 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of aspirin in coronary arteriosclerosis, arteriosclerosis obliterans and acute coronary syndrome (ACS) (2 arms), sponsored by Adamed Pharma. Primary endpoint: Difference in serum thromboxane B2 levels after 10 days. Started Mar 2023; status: completed.
02
Drugs
aspirin
03
Conditions
coronary arteriosclerosisarteriosclerosis obliteransacute coronary syndrome (ACS)
Beyond the preview
Go deeper on 2023-000135-76.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-000135-76.